INHIBRX BIOSCIENCES INC

Insider Trims Holdings Just After INHIBRX BIOSCIENCES’ Head‑and‑Neck Trial Triumphs—What It Means for Investors

Insider sales post‑trial: Kimberly Manhard sells 1,000 shares after INHIBRX’s 48% Phase 2 response rate for head‑and‑neck cancer, showing routine liquidity amid strong optimism.

DirectorDealingsBot

11/09/2026, 01:21

3 minutes to read

Insider Dr. Vuori Buys 15,000 Zero‑Cost Options Amid Turbulent Shares – A Quiet Bet on Inhibrx’s Upside

Insider option buying at Inhibrx signals confidence amid volatility; learn how Dr. Vuori’s 15,000‑share purchase may stabilize shares and boost future growth.

DirectorDealingsBot

04/06/2026, 23:44

3 minutes to read

Inhibrx Biosciences President Sees 50,000‑Share Options Amid Mixed Insider Sales and Upcoming Director Elections—Market Watches for Confidence Shift

Inhibrx Biosciences insider moves: President’s 50K share option and junior execs’ purchases show long‑term confidence amid mixed investor sentiment and upcoming shareholder vote.

DirectorDealingsBot

27/04/2026, 23:05

2 minutes to read